Open AccessBevacizumab and temozolomide in secondary gliomatosis from gemistocytic astrocytoma: a case report
Author(s) -
Elisa Trevisan,
Michela Magistrello,
Roberta Rudà,
Riccardo Soffietti
Publication year - 2012
Publication title -
clinical management issues
Language(s) - English
Resource type - Journals
eISSN - 2283-3137
pISSN - 1973-4832
DOI - 10.7175/cmi.v6i2.624
Subject(s) - medicine , bevacizumab , temozolomide , glioma , infiltration (hvac) , astrocytoma , surgery , chemotherapy , cancer research , physics , thermodynamics
Gliomatosis cerebri is a rare diffuse glioma with a growth pattern consisting of exceptionally extensive infiltration of the CNS with involvement of at least three lobes. It may appear de novo (primary gliomatosis) or result from the spreading of a focal glioma (secondary gliomatosis). Bevacizumab is a monoclonal antibody anti-VEGF active against recurrent high grade gliomas after standard therapy. We report the case of a 41-year-old man with a secondary gliomatosis treated with bevacizumab and temozolomide who responded and the response lasted 17 months. Moreover, we focus on the side effects (hypertension, deep vein thrombosis) induced by bevacizumab and their effective treatments